Related Experiment Video

Updated: Jun 7, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Jirí Pavlu1, Richard M Szydlo, John M Goldman

  • 1Department of Haematology, Imperial College at Hammersmith Hospital, London, UK. jiri.pavlu@imperial.nhs.uk

Blood
|October 23, 2010
PubMed

Insights

Hematopoietic stem cell transplantation has been a curative treatment for chronic myeloid leukemia (CML) for 30 years. While tyrosine kinase inhibitors are effective, transplantation remains crucial for resistant cases and offers new therapeutic strategies.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Immunology

Background:

  • Hematopoietic stem cell transplantation (HSCT) has been a cornerstone in treating chronic myeloid leukemia (CML) for three decades.
  • Evolution of HSCT techniques progressed from identical twins to HLA-identical siblings and unrelated donors, making CML a leading indication for allogeneic transplantation.
  • The biological characteristics of CML, including its homogeneity, graft-versus-leukemia effect, and monitoring capabilities, positioned it at the forefront of transplantation research.

Purpose of the Study:

  • To review the historical development and current role of hematopoietic stem cell transplantation in managing chronic myeloid leukemia.
  • To highlight the significance of HSCT as a curative option, particularly for patients refractory to or intolerant of tyrosine kinase inhibitors.
  • To explore emerging strategies combining tyrosine kinase inhibitors with transplantation for CML and other malignancies.

Main Methods:

  • Review of historical data and clinical outcomes of HSCT for CML.
  • Analysis of the impact of advancements in transplantation techniques and donor selection.
  • Evaluation of the integration of BCR-ABL1 tyrosine kinase inhibitors with HSCT.

Main Results:

  • HSCT has demonstrated long-term curative potential for chronic myeloid leukemia over 30 years.
  • CML became the most frequent indication for allogeneic HSCT globally during the 1990s.
  • Tyrosine kinase inhibitors provide long-term disease control for most CML patients, but HSCT remains vital for non-responders or intolerant individuals.

Conclusions:

  • Hematopoietic stem cell transplantation remains an effective therapeutic option for chronic myeloid leukemia, especially when tyrosine kinase inhibitors fail.
  • The combination of tyrosine kinase inhibitors and HSCT represents a promising new strategy for CML management.
  • This combined approach offers potential inspiration for treating other hematologic malignancies.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...